Results 71 to 80 of about 21,441 (140)

Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients

Clinical Transplantation, Volume 40, Issue 2, February 2026.
ABSTRACT Background and Aims Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long‐term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB‐4) score and FibroScan.
Emilie Høegholm Ernst Lauridsen, Rasmus Hvidbjerg Gantzel, Moises Alberto Suarez‐Zdunek, Mette Bak Nielsen, Allan Rasmussen, Susanne Dam Nielsen, Henning Grønbæk, Gerda Elisabeth Villadsen   +7 more
wiley   +1 more source

Autoimmune Hepatitis: Histopathological Diversity and Its Clinical Implications

Hepatology Research, Volume 56, Issue 2, Page 139-147, February 2026.
ABSTRACT Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease characterized by diverse clinical and histological manifestations. Accurate histopathological evaluation plays a critical role in determining disease activity, guiding treatment strategies, and predicting prognosis.
Mina Komuta, Kenichi Harada
wiley   +1 more source

Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background and Aims We investigated the associations between SLD, fibrosis stage, and all‐cause and cause‐specific mortality, with a focus on SLD subtypes. Methods We analysed 486 156 UK Biobank participants. SLD cases were identified using fatty liver index ≥ 60. Causes of death were confirmed via death registries.
Qi Feng, Pinelopi Manousou, Chioma N. Izzi‐Engbeaya, Rohit Loomba, Mark Thursz, Mark Woodward   +5 more
wiley   +1 more source

Drug-Induced Sclerosing Cholangitis Leading to Discontinuation of Treatment in a Patient with Metastatic Breast Cancer: A Case Report. [PDF]

Case Rep Oncol
Aso S, Shimomura A, Hirai H, Honda Y, Misumi K, Watadani T, Aso K, Kitagawa D, Shimizu C.   +8 more
europepmc   +1 more source

Secondary Sclerosing Cholangitis in a Critically Ill Burn Patient: A Case Report and Review of the Literature. [PDF]

Clin Case Rep
Siniora AN, Marouf O, Arekat RR, Abuhilal FA, Salah MI, AbuBaha M, Salameh H, Taha HM.   +7 more
europepmc   +1 more source

Burden of primary sclerosing cholangitis in Sweden (2002-2020): Incidence, outcomes, healthcare utilization, and costs. [PDF]

Hepatol Commun
Bergquist A, Kachru N, Aldvén M, Ström O, Skröder H, Toresson Grip E, Hagström H.   +6 more
europepmc   +1 more source

MUC1 as a biomarker in primary sclerosing cholangitis and cholangiocarcinoma. [PDF]

Ann Gastroenterol
Hashash JG, Beatty P, Yan IK, Nakhleh R, Camilleri M, Harnois D, Farraye FA, Francis FF.   +7 more
europepmc   +1 more source

Primary Sclerosing Cholangitis [PDF]

New England Journal of Medicine, 2016
Roberto, Valente, Marco, Del Chiaro, Urban, Arnelo   +2 more
openaire   +5 more sources

Biliary Reconstruction in Liver Transplantation with Primary Sclerosing Cholangitis: Roux-en-Y Hepaticojejunostomy or Duct-to-Duct Anastomosis? [PDF]

J Clin Med
Dancs PT, Pohlmann MC, Bednarsch J, Rashidi-Alavijeh J, Schmitz SM, Kroh A, Ulmer F, Vondran FWR, Neumann UP, Hoyer DP, Heise D.   +10 more
europepmc   +1 more source

Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial. [PDF]

BMJ Open
Cristoferi L, D'Amato D, Maino C, Bernasconi D, Dinelli ME, Malandrin SMI, Facciotti F, Festa MM, Gerussi A, Rossi E, Malinverno F, Tettamanti P, Cazzaniga ME, Corso R, Ippolito D, Galimberti S, Invernizzi P, Carbone M.   +17 more
europepmc   +1 more source